Physician profile
Kayla Teives
NPI 1124565239
$9,515.19
in general payments reported to CMS, 2019-2025
28 companies · $1,135 in 2025
The $1,135 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,851 · 2022: $2,249 · 2023: $2,192 · 2024: $1,088 · 2025: $1,135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,415.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,414.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,902.98 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,511.38 | 2021-2025 | Caplyta |
| Astrazeneca Pharmaceuticals Lp | $800.34 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Vanda Pharmaceuticals INC. | $557.89 | 2021-2025 | Fanapt, Hetlioz |
| Neurocrine Biosciences, INC. | $541.99 | 2021-2025 | Ingrezza |
| Alkermes, INC. | $507.34 | 2021-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $482.00 | 2021-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Otsuka America Pharmaceutical, INC. | $475.14 | 2021-2024 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $333.47 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Gilead Sciences, INC. | $271.79 | 2021-2025 | Descovy |
| Biohaven Pharmaceuticals, INC. | $255.75 | 2021 | |
| Glaxosmithkline, LLC. | $254.92 | 2021-2024 | Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $253.59 | 2021-2025 | Trintellix |
| Biohaven Pharmaceutical Holding Company Ltd. | $219.97 | 2022 | |
| Janssen Pharmaceuticals, INC | $213.53 | 2021-2025 | Invega Sustenna, Spravato, Invega Trinza |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $193.16 | 2021 | |
| Idorsia Pharmaceuticals US INC | $192.79 | 2022-2025 | Quviviq, Quviviq |
| Novo Nordisk INC | $145.00 | 2022-2025 | Rybelsus, Ozempic |
| Indivior INC. | $110.59 | 2021-2025 | Perseris, Sublocade |
| Exact Sciences Corporation | $87.00 | 2023-2025 | Cologuard Collection Kit |
| Eisai INC. | $78.82 | 2021 | |
| Merck Sharp & Dohme LLC | $22.31 | 2024 | Vaxneuvance, Gardasil 9, Capvaxive |
| Tandem Diabetes Care, INC. | $22.17 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Axsome Therapeutics, INC. | $20.43 | 2023 | Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $19.79 | 2024 | |
| Lilly USA, LLC | $14.31 | 2021 | |
| Almatica Pharma LLC | $13.90 | 2024 | Loreev Xr |
| Ironshore Pharmaceuticals INC. | $12.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kayla Teives listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.